Companies Dominating the Oncolytic Virus Therapy Landscape
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Shanghai Sunway Biotech Co. Ltd.
- Oncolys BioPharma Inc.
- TILT Biotherapeutics Ltd.
- Oncorus Inc
- TAKARA BIO INC.
- Vyriad
- Transgene SA
- Lokon Pharma AB
- Pfizer Inc.
- Rigvir Group
- Sibiono GeneTech Co. Ltd.
- Oncolytics Biotech
- Daiichi Sankyo
- Kissei Pharmaceutical Co., Ltd.
- Boehringer Ingelheim
Browse Key Market Insights with Data Illustration:
In the News
- Daiichi Sankyo announced that it has received approval for its oncolytic virus G47 (trade name: DELYTACT). The approval is primarily based on the Japan Ph2 research (investigator led-study) findings led by Dr. Todo of the Institute of Medical Science, The University of Tokyo undertaken in patients with residual or recurrent glioblastoma.
- TILT Biotherapeutics Ltd. partnered with Biotheus Inc. to promote the global development and marketing of TILT-123, a cancer treatment product, and also make it available to Chinese cancer patients. Further, the agreement involves a down payment as well as payments at specified points in the clinical research process and is qualified to collect large royalties on future sales payments.
